2024-512123-37-00招募中3 期
58-week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 487
- 试验地点
- 59
- 主要终点
- To Evaluate the safety and tolerability of long-term administration of tavapadon in subjects with PD: •Nature, frequency, and temporality of TEAEs (nonserious and serious), including abuse related AEs and AEs related to MHIs •Frequency of discontinuations •QUIP RS •ESS •C-SSRS •SMWQ •Clinical laboratory evaluations •Vital signs •Physical and neurological examinations •ECGs
研究概览
简要总结
To evaluate the safety and tolerability of long-term administration of tavapadon in subjects with PD.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Subjects who complete the 27-week double-blind Treatment Period of Trial CVL-751-PD-001 or Trial CVL-751-PD-003 or the 27-week doubleblind Treatment Period and 10-day Safety/Withdrawal Assessment Period of Trial CVL-751-PD-002 and enter this trial within 72 hours after completing the last trial visit in the double-blind trial. Rollover subjects from Trial CVL-751-PD-003 must continue to use levodopa/carbidopa (or levodopa/benserazide) for the duration of the trial.
- •Sexually active men or women of childbearing potential must agree to use acceptable (at minimum) or highly effective birth control or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
- •Subjects who are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Subjects who are able, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.
- •Subjects who, in the judgement of the investigator, demonstrated adequate compliance with the IMP and protocol requirements in the double-blind trial.
- •Subjects who are willing and able to refrain from any PD medications that are not permitted by the protocol (including dopaminergic agents) throughout participation in the trial.
排除标准
- •Rollover Subjects:
- •Subjects who do not enroll in this open-label trial within 72 hours after completing the last trial visit in the double-blind trial.
- •Subjects who, in the judgement of the investigator, experienced poor tolerability to the IMP during the double-blind trial or whose safety assessments resulted in new concerns that would suggest that the subject may not be appropriate for a 58-week trial of tavapadon.
- •Subjects who, in the judgment of the investigator, were noncompliant with trial procedures or with IMP administration during the double-blind trial.
- •Subjects who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Subjects who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 CSSRS Suicidal Behavior Items occurred within the last 2 years, OR Subjects who, in the opinion of the investigator, present a serious risk of suicide.
- •Subjects who, in the judgment of the investigator, had a clinically significant medical, surgical, psychiatric, or laboratory abnormality after completing the last trial visit in the double-blind trial that would compromise participation in this trial.'
- •Subjects who had previously been enrolled in this open-label trial and had subsequently withdrawn.
结局指标
主要结局
To Evaluate the safety and tolerability of long-term administration of tavapadon in subjects with PD: •Nature, frequency, and temporality of TEAEs (nonserious and serious), including abuse related AEs and AEs related to MHIs •Frequency of discontinuations •QUIP RS •ESS •C-SSRS •SMWQ •Clinical laboratory evaluations •Vital signs •Physical and neurological examinations •ECGs
To Evaluate the safety and tolerability of long-term administration of tavapadon in subjects with PD: •Nature, frequency, and temporality of TEAEs (nonserious and serious), including abuse related AEs and AEs related to MHIs •Frequency of discontinuations •QUIP RS •ESS •C-SSRS •SMWQ •Clinical laboratory evaluations •Vital signs •Physical and neurological examinations •ECGs
次要结局
- To Evaluate the effects of tavapadon on PD symptoms during long-term treatment • Change from baseline in the MDS-UPDRS Parts I, II, and III scores • Change from baseline in the Hauser diary (only in subjects who require daily L-Dopa or equivalent therapy for symptom control at the time of enrollment) • Change from baseline in the EQ-5D-5L index and VAS scores
- To evaluate the effects of tavapadon on L-Dopa usage: •Change from baseline in L-Dopa usage
- To Evaluate speech and facial expression characteristics of subjects with PD: •Exploratory analyses of audio and video data collected from subject administered remote digital testing of speech and facial expressions through an interactive application platform on the subject's personal mobile device may be conducted
研究者
Stephanie Pfister
Scientific
Cerevel Therapeutics LLC
研究点 (59)
Loading locations...
相似试验
尚未招募
不适用
An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection in Patients With Primary Parkinson's DiseaseParkinson's DiseaseNCT07279844Anhui Provincial Hospital6
进行中（未招募）
3 期
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisAtopic DermatitisNCT07265479Organon and Co187
招募中
2 期
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic DermatitisAtopic Dermatitis2024-519795-11-00Apogee Therapeutics Inc.79
招募中
2 期
A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington’s Disease2023-504628-24-00PTC Therapeutics Inc.172
招募中
2 期
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07266441Janssen Research & Development, LLC157